96 related articles for article (PubMed ID: 20081324)
1. Obesity as a risk factor for coronary events in Japanese patients with hypercholesterolemia on low-dose simvastatin therapy.
Saito Y; Kita T; Mabuchi H; Matsuzaki M; Matsuzawa Y; Nakaya N; Oikawa S; Sasaki J; Shimamoto K; Itakura H
J Atheroscler Thromb; 2010 Mar; 17(3):270-7. PubMed ID: 20081324
[TBL] [Abstract][Full Text] [Related]
2. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT).
Mabuchi H; Kita T; Matsuzaki M; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Sasaki J; Shimamoto K; Itakura H;
Circ J; 2002 Dec; 66(12):1096-100. PubMed ID: 12499612
[TBL] [Abstract][Full Text] [Related]
3. Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT).
Oikawa S; Kita T; Mabuchi H; Matsuzaki M; Matsuzawa Y; Nakaya N; Saito Y; Sasaki J; Shimamoto K; Itakura H;
Atherosclerosis; 2007 Apr; 191(2):440-6. PubMed ID: 16765358
[TBL] [Abstract][Full Text] [Related]
4. Primary cardiovascular events and serum lipid levels in elderly Japanese with hypercholesterolemia undergoing 6-year simvastatin treatment: a subanalysis of the Japan lipid intervention trial.
Horiuchi H; Kita T; Mabuchi H; Matsuzaki M; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Sasaki J; Shimamoto K; Itakura H;
J Am Geriatr Soc; 2004 Dec; 52(12):1981-7. PubMed ID: 15571531
[TBL] [Abstract][Full Text] [Related]
5. The risk of cardiovascular events in Japanese hypertensive patients with hypercholesterolemia: sub-analysis of the Japan Lipid Intervention Trial (J-LIT) Study, a large-scale observational cohort study.
Shimamoto K; Kita T; Mabuchi H; Matsuzaki M; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Sasaki J; Itakura H;
Hypertens Res; 2005 Nov; 28(11):879-87. PubMed ID: 16555576
[TBL] [Abstract][Full Text] [Related]
6. [Results of clinical epidemiology and intervention trial of hyperlipidemia in Japan].
Itakura H
Nihon Rinsho; 2002 May; 60(5):889-98. PubMed ID: 12029990
[TBL] [Abstract][Full Text] [Related]
7. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.
Haffner SM; Alexander CM; Cook TJ; Boccuzzi SJ; Musliner TA; Pedersen TR; Kjekshus J; Pyörälä K
Arch Intern Med; 1999 Dec 13-27; 159(22):2661-7. PubMed ID: 10597756
[TBL] [Abstract][Full Text] [Related]
8. Large-scale cohort study on the relationship between serum lipid concentrations and risk of cerebrovascular disease under low-dose simvastatin in Japanese patients with hypercholesterolemia: sub-analysis of the Japan Lipid Intervention Trial (J-LIT).
Nakaya N; Kita T; Mabuchi H; Matsuzaki M; Matsuzawa Y; Oikawa S; Saito Y; Sasaki J; Shimamoto K; Itakura H;
Circ J; 2005 Sep; 69(9):1016-21. PubMed ID: 16127179
[TBL] [Abstract][Full Text] [Related]
9. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S).
Miettinen TA; Pyörälä K; Olsson AG; Musliner TA; Cook TJ; Faergeman O; Berg K; Pedersen T; Kjekshus J
Circulation; 1997 Dec; 96(12):4211-8. PubMed ID: 9416884
[TBL] [Abstract][Full Text] [Related]
10. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Yokoyama M; Origasa H;
Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313
[TBL] [Abstract][Full Text] [Related]
11. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients.
Matsuzawa Y; Kita T; Mabuchi H; Matsuzaki M; Nakaya N; Oikawa S; Saito Y; Sasaki J; Shimamoto K; Itakura H;
Circ J; 2003 Apr; 67(4):287-94. PubMed ID: 12655157
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment.
Wilhelmsen L; Pyörälä K; Wedel H; Cook T; Pedersen T; Kjekshus J
Eur Heart J; 2001 Jul; 22(13):1119-27. PubMed ID: 11428852
[TBL] [Abstract][Full Text] [Related]
13. Better lipid target achievement for secondary prevention through disease management programs for diabetes mellitus and coronary heart disease in clinical practice in Germany.
Gitt AK; Sonntag F; Jannowitz C; Weizel A; Karmann B; Schaefer JR; Pittrow D; Hildemann SK
Curr Med Res Opin; 2016; 32(3):417-26. PubMed ID: 26568400
[TBL] [Abstract][Full Text] [Related]
14. Benefits of early lipid-lowering intervention in high-risk patients: the lipid intervention strategies for coronary patients study.
Pedersen TR; Jahnsen KE; Vatn S; Semb AG; Kontny F; Zalmai A; Nerdrum T
Clin Ther; 2000 Aug; 22(8):949-60. PubMed ID: 10972631
[TBL] [Abstract][Full Text] [Related]
15. Gender difference in coronary events in relation to risk factors in Japanese hypercholesterolemic patients treated with low-dose simvastatin.
Sasaki J; Kita T; Mabuchi H; Matsuzaki M; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Shimamoto K; Kono S; Itakura H;
Circ J; 2006 Jul; 70(7):810-4. PubMed ID: 16799230
[TBL] [Abstract][Full Text] [Related]
16. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P
Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834
[TBL] [Abstract][Full Text] [Related]
17. Effects of celiprolol and simvastatin on the calculated risk of coronary heart disease (the Celisimva study).
Olkinuora JT; Viikari J; Vanhanen H; Makkonen N; Kalliomäki T
Scand Cardiovasc J; 2006 Jun; 40(3):160-6. PubMed ID: 16798663
[TBL] [Abstract][Full Text] [Related]
18. Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study).
Garmendia F; Brown AS; Reiber I; Adams PC
Curr Med Res Opin; 2000; 16(3):208-19. PubMed ID: 11191012
[TBL] [Abstract][Full Text] [Related]
19. Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients.
Averna M; Zaninelli A; Le Grazie C; Gensini GF
J Clin Lipidol; 2010; 4(4):272-8. PubMed ID: 21122660
[TBL] [Abstract][Full Text] [Related]
20. Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia.
Toth PP; Catapano AL; Farnier M; Foody J; Tomassini JE; Jensen E; Polis AB; Hanson ME; Musliner TA; Tershakovec AM
Am J Cardiol; 2016 Dec; 118(12):1812-1820. PubMed ID: 27756478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
